奧米加干擾素
奧米加干擾素（Interferon-omega）是一種源自貓的重組**第一型干擾素**，具有強效的免疫調節與抗病毒作用。 * **獸醫應用**：主要用於治療嚴重的病毒感染，特別是**犬小病毒（Canine Parvovirus）**與貓反轉錄病毒（**貓白血病 FeLV 與貓愛滋 FIV**）。 * **跨物種療效**：**臨床要點：** 雖然它是貓源性蛋白質，但由於第一型干擾素具有跨物種的受體親和力，因此對狗也非常有效。然而，狗若長期使用可能會產生中和抗體。 * **新興應用**：在治療犬異位性皮膚炎、貓傳染性腹膜炎（FIP）、貓卡里西病毒（FCV）以及貓疱疹病毒（FHV-1）引起的皮膚炎或角膜炎方面，已顯示出潛在益處。 * **取得方式**：在歐盟及其他地區有商業販售，但在美國尚未上市（需透過恩慈療法合法專案進口）。
作用機制: Interferon-omega does not act as a direct virucidal agent. Instead, it induces an antiviral state in host cells: 1. **Receptor Binding**: Binds to specific type I interferon receptors on the surface of target cells. 2. **Signal Transduction**: Activates the **JAK-STAT signaling pathway**. 3. **Gene Transcription**: Induces the transcription of interferon-stimulated genes (ISGs). 4. **Antiviral Proteins**: Leads to the production of key enzymes such as **2'-5' oligoadenylate synthetase (OAS)** and **protein kinase R (PKR)**. 5. **Viral Inhibition**: These enzymes inhibit viral mRNA translation and degrade viral RNA → effectively halting viral replication. Additionally, it nonspecifically enhances host immune defense mechanisms by stimulating natural killer (NK) cells and macrophages.
各物種劑量
- Treatment of FeLV and/or FIV (non-terminal clinical stages) · 1 million Units/kg SC once daily · SC · q24h · 5 days (Three separate 5-day treatments performed at day 0, day 14, and day 60)
- FHV-1 facial dermatitis · Day 0: 1.5 million Units/kg (half peri-lesionally/intradermally, half SC). Day 2 and 9: 1.5 million Units/kg SC. Days 19, 21, and 23: 0.75 million Units/kg peri-lesionally/intradermally + 0.75 million Units/kg SC. · SC / Intradermal / Peri-lesional · Specific days · 23 days · Cat was sedated with propofol for peri-lesional and intradermal injections.
- Treatment of parvovirus (enteric form) · 2.5 million Units/kg IV once daily · IV · q24h · 3 days · The earlier the dog is treated, the more likely of success.
- Treatment of atopic dermatitis · Dogs 8-15 kg = 1 million Units; 15-29 kg = 2 million Units; 29-40 kg = 3 million Units; >40 kg = 4 million Units · SC · Specific days · Days 0, 3, 7, 14, 21, 35, 56, 90, 120, & 150 · Further larger-scale studies needed to confirm cost-effectiveness and safety for long-term treatment.
- Parvovirus · 2.5 million units/kg · IV · q24h · 3 days
劑量為合格獸醫專業人員的臨床參考。請務必對照最新藥品仿單及個別病患確認。
給藥途徑
禁忌症
- Concurrent vaccination in dogs (wait until fully recovered)
- Vaccination in cats during and after treatment (due to the immunosuppressive nature of FeLV/FIV)
- Substitution with human interferons (alpha, beta, or gamma)
- No specific contraindications available in the monograph
不良反應
- Hyperthermia (typically 3-6 hours post-dose)
- Vomiting
- Soft feces or mild diarrhea (cats)
- Transient fatigue or lethargy (cats)
- Slight decreases in RBCs, WBCs, and platelets (usually resolves within a week)
- Increased ALT (usually resolves within a week)
- Antibody formation in dogs (with prolonged or repeated treatment)
- Transient fatigue
- Hyperthermia
- Mild diarrhoea
- Decreased WBCs (leukopenia)
- Decreased platelets (thrombocytopenia)
- Decreased RBCs (anaemia)
- Increased liver enzyme activities
- Ocular irritation (with topical use in cats)
- Immune-mediated diseases (reported with long-term administration in humans)
藥物相互作用
- Hepatotoxic drugs · May increase the risk of liver toxicity; use with caution.
- Myelosuppressive drugs · May increase the risk of bone marrow suppression; use with caution.
- Vaccines · Should not be administered concurrently until the animal has clinically recovered. · major
- Antibiotics · Improves prognosis; no negative interactions observed. · null
- NSAIDs · Improves prognosis; no negative interactions observed. · null
監測
- Clinical efficacy (resolution of viral infection signs)
- Complete Blood Count (CBC) to monitor for myelosuppression
- Hepatic function tests (ALT)
- Complete Blood Count (WBCs, RBCs, platelets)
- Liver enzyme activities
- Body temperature
- Clinical signs of gastrointestinal upset or fatigue
過量
In safety studies, 10X overdoses in dogs and cats caused mild lethargy/somnolence, slight hyperthermia, and slight increases in respiratory and heart rates. In all animals tested, clinical signs resolved within 7 days and no specific treatment was required.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。